Tribune News Service
New Delhi, December 7
After Pfizer, the Serum Institute of India and Bharat Biotech today applied to the central drug regulator seeking emergency use authorisation for their Covid-19 vaccine, official sources said.
While Serum Institute is working on Covishield in collaboration with Oxford University and pharma firm AstraZeneca, Bharat Biotech’s Covaxin is being developed indigenously in collaboration with the Indian Council of Medical Research.
Soon after SII chief Adar Poonawalla said the firm had applied for emergency use authorisation in respect of Covishield before the end of 2020, the government said these “are encouraging developments”.
An expert panel of the Central Drugs Standard Control Organisation would reportedly review on Wednesday the applications of Pfizer, Serum Institute of India and Bharat Biotech.
Pfizer vs Serum Institute
Between Pfizer and Serum vaccines, experts say the latter is more suitable to Indian conditions in terms of pricing, storage and transport.
Active cases below 4L
India’s Covid active cases on Monday came down to 3,96,729, which is 4.1 per cent of the total infections.